{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:04:40Z","timestamp":1755216280895,"version":"3.43.0"},"reference-count":11,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Summary:<\/jats:title>\n               <jats:p>Oncogenic KRAS is a hallmark of pancreatic cancer, one of the deadliest malignancies, and inhibition of oncogenic KRAS alone is, in most patients, not sufficient to eradicate the tumor. The two studies by Stanger and colleagues and Lowe and colleagues propose combination therapy approaches to leverage the power of the immune system, together with KRAS inhibition, to achieve long-term remission.<\/jats:p>\n               <jats:p>See related article by Orlen et al., p. 1697<\/jats:p>\n               <jats:p>See related article by Broderick et al., p. 1717<\/jats:p>","DOI":"10.1158\/2159-8290.cd-25-0878","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:06:42Z","timestamp":1754291202000},"page":"1537-1539","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two Shots on Goal: Combination of RAS Inhibition and Immunotherapy Drives Long-term Remission in Pancreatic Cancer"],"prefix":"10.1158","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-9459","authenticated-orcid":false,"given":"Emily L.","family":"Lasse Opsahl","sequence":"first","affiliation":[{"name":"1Graduate Program in Cancer Biology, The University of Michigan Medical School, Ann Arbor, Michigan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-9035","authenticated-orcid":false,"given":"Marina","family":"Pasca di Magliano","sequence":"additional","affiliation":[{"name":"2Department of Surgery, The University of Michigan Medical School, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."},{"name":"4Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2025080403063532500_bib1","first-page":"1717","article-title":"A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in PDAC","volume":"15","author":"Broderick","year":"2025","journal-title":"Cancer Discov"},{"key":"2025080403063532500_bib2","first-page":"1697","article-title":"T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma","volume":"15","author":"Orlen","year":"2025","journal-title":"Cancer Discov"},{"key":"2025080403063532500_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"2025080403063532500_bib4","first-page":"132","article-title":"\u201cUndruggable KRAS\u201d: druggable after all","volume":"39","author":"Cox","year":"2025","journal-title":"Genes Dev"},{"key":"2025080403063532500_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J Clin Invest"},{"key":"2025080403063532500_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"2025080403063532500_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"2025080403063532500_bib8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"2025080403063532500_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"2025080403063532500_bib10","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov"},{"key":"2025080403063532500_bib11","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1158\/2159-8290.CD-23-0013","article-title":"Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early neoplastic lesions","volume":"13","author":"Carpenter","year":"2023","journal-title":"Cancer Discov"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/15\/8\/1537\/3636430\/cd-25-0878.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/15\/8\/1537\/3636430\/cd-25-0878.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:06:43Z","timestamp":1754291203000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/15\/8\/1537\/763855\/Two-Shots-on-Goal-Combination-of-RAS-Inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":11,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-0878","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"type":"print","value":"2159-8274"},{"type":"electronic","value":"2159-8290"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}